Catalog No.
EHD80901
Expression system
Mammalian Cells
Species
Homo sapiens (Human)
Protein length
Met1-Lys379
Predicted molecular weight
41.26 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P28908
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
CD30L receptor, Ki-1 antigen, CD30, TNFRSF8, D1S166E, Tumor necrosis factor receptor superfamily member 8, Lymphocyte activation antigen CD30
Case Report: Flow cytometric differential diagnosis of a peripheral T-cell lymphoma, NOS with complete loss of CD45 and dim expression of CD3., PMID:40510503
Primary Mediastinal Large B-cell Lymphoma: A Diagnostic Conundrum., PMID:40487560
161Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas., PMID:40456588
Traumatic Ulcerative Granuloma with Stromal Eosinophilia: From Reactive Process to Low Grade CD30 + lymphoproliferative Disorder., PMID:40419719
Case Report: Bispecific CD20/CD30-targeted chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma., PMID:40406106
Multiplex Lateral Flow Assay Combining CD30 and IL-10 for the Detection of BIA-ALCL., PMID:40366904
Dupilumab-associated lymphoproliferative disorders: a comprehensive review on clinicohistopathologic features and underlying mechanisms., PMID:40349527
HIV-Tat upregulates the expression of senescence biomarkers in CD4+ T-cells., PMID:40342418
[Articular and periarticular tumors : Important diagnoses in rheumatology and orthopedic rheumatology]., PMID:40323421
Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-Analysis., PMID:40280037
Expression of functionally glycosylated PSGL-1 in ALK-positive anaplastic large cell lymphoma., PMID:40267632
Versatile intact LC-MS method for evaluating the drug-antibody ratio and drug load distribution of antibody-drug conjugates in human plasma., PMID:40267607
Serum Protein Profiling as theranostic biomarkers for Left- and Right-Sided Colon Cancer using Luminex® technology., PMID:40232184
Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directions., PMID:40227173
Molecular heterogeneity of CD30+ peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre study., PMID:40215750
Primary Cutaneous Anaplastic Large Cell Lymphoma With TCR-γδ Expression: A Case Series of Eleven Patients of a Rare Immunophenotypic Variant., PMID:40202044
[Clinicopathological features and prognostic value of CD30 expression in EBV-positive diffuse large B cell lymphoma]., PMID:40159025
No Distinct Cytokine, Chemokine, and Growth Factor Blood Profile Associated With Monkeypox Virus Clade IIb Infected Patients., PMID:40156483
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers., PMID:40140364
Characterization Of Beta Thalassaemia Mutations In Patients Having Borderline Haemoglobin A2 Levels., PMID:40121643
Retrospective Evaluation of Clinical and Follow-Up Outcomes in Primary Cutaneous CD30+ Lymphoproliferative Disorders., PMID:40045743
Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule., PMID:39958564
ICOSL, OX40L, and CD30L control persistence of asthmatic CD4 tissue-resident memory CD4 T cells., PMID:39921040
Intraoral Lymphomatoid Papulosis Type D Showing Scarce/Absent CD30 Expression in A Pediatric Patient: Case Report and Literature Review., PMID:39907858
Development of chimeric Nanobody-Granzyme B functionalized ferritin nanoparticles for precise tumor therapy., PMID:39880067
HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+ lymphoma., PMID:39841453
Targeted immunotherapy in the treatment of childhood and adolescent classic Hodgkin lymphoma., PMID:39820376
Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis., PMID:39815050
Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis., PMID:39806291
Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL)., PMID:39800801
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma., PMID:39786430
T cell malignancies after CAR T cell therapy in the DESCAR-T registry., PMID:39779930
Follicular Helper T-cell Lymphoma With Hodgkin/Reed-Sternberg-Like Cells Versus Classic Hodgkin Lymphoma: A Comparative Study., PMID:39758028
CD30- and CD56-positive atypical intravascular lymphocytes of the uterine cervix, mimicking intravascular lymphoma: A case report and review of the literature., PMID:39721713
Identifying potential drug targets for myocardial infarction through Mendelian randomization., PMID:39715222
Preclinical evaluation of 64Cu/177Lu-labelled anti-CD30 monoclonal antibody for theranostics in CD30-positive lymphoma., PMID:39688699
When should we use it? The role of brentuximab vedotin in 2024., PMID:39644065
BV and beyond: how to incorporate novel agents into PTCL management., PMID:39644004
High expression of RHOF is an effective diagnostic marker and a potential prognostic indicator for primary mediastinal large B-cell lymphoma., PMID:39630231
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma., PMID:39622165
Comparison of CD30L and OX40L Reveals CD30L as a Promising Therapeutic Target in Atopic Dermatitis., PMID:39589186
A case of karyomegalic interstitial nephritis without FAN1 mutations in the setting of brentuximab, ifosfamide, and carboplatin exposure., PMID:39543462
A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas., PMID:39531538
Severe subacute onset sensorimotor polyneuropathy associated with brentuximab vedotin treatment for refractory classical Hodgkin's lymphoma., PMID:39500584
Refining Diagnostic Subtypes of Peripheral T-Cell Lymphoma Using a Multiparameter Approach., PMID:39491745
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma., PMID:39478125
[Clinical study of immune-targeting combined with attenuated chemotherapy in the treatment of children with classic Hodgkin lymphoma]., PMID:39429083
Systemic ALK-negative anaplastic large cell lymphoma: Insights into morphologic, immunophenotypic, genetic and molecular characteristics., PMID:39424106
CD30 influences germinal center B-cell dynamics and the expansion of IgG1-switched B cells., PMID:39420111
S100 and CD34 positive spindle cell tumors of the uterine cervix with EGFR mutation: a hitherto unrecognized neoplasm phenotypically and epigenetically overlapping with "NTRK-rearranged spindle cell neoplasms" of the uterus., PMID:39387892
For research use only. Not for human or drug use.
